Clinical Trials Logo

H7N9 Influenza clinical trials

View clinical trials related to H7N9 Influenza.

Filter by:
  • None
  • Page 1

NCT ID: NCT06417853 Not yet recruiting - H7N9 Influenza Clinical Trials

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)

HD-MAP
Start date: July 5, 2024
Phase: Phase 1
Study type: Interventional

Study SP-1219-007 is a multi-centre, randomised, study designed to access the safety and tolerability of two doses of monovalent Influenza A (H7N9) vaccine delivered intradermally by a microarray patch delivery system in healthy adults aged 18 to 50 years.

NCT ID: NCT03755427 Not yet recruiting - H7N9 Influenza Clinical Trials

A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine

Start date: November 2018
Phase: Phase 2
Study type: Interventional

The aim of this study is to investigate the immunogenicity and safety of the inactivated whole-virion vaccine for teenagers and adults. The investigators will test the vaccine in participants aged above 12 years, for a randomized, blind, placebo-controlled, clinical study. The investigators designed one dosage groups: 15 μg of hemagglutinin antigen. Control group is designed to inoculate seasonal influence vaccine and aluminum hydroxide adjuvant. Participants will receive 2 doses of vaccine at 21-day intervals. Safety up to 6 months and changes in hemagglutinin inhibition (HI) titers at 21 days after each vaccination will be determined.

NCT ID: NCT03369808 Active, not recruiting - H7N9 Influenza Clinical Trials

A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine

Start date: December 29, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to investigate the immunogenicity and safety of the inactivated whole-virion vaccine for teenagers and adults. The investigators will test the vaccine in participants aged 12-60 years, for a randomized, blind, placebo-controlled, age-stratified clinical study. The investigators designed three dosage groups: 7.5 μg,15 μg and 30 μg of hemagglutinin antigen. According to the age of the subjects, Each group was divided into different age subgroups. Phosphate buffer solution and Aluminum hydroxide adjuvant as placebo controls were both set up in the subgroups.Participants will receive 2 doses of vaccine at 21-day intervals.Safety up to 6 months and changes in hemagglutinin inhibition (HI) titers at 21 days after each vaccination were determined.

NCT ID: NCT03330899 Completed - Influenza Clinical Trials

Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil

Start date: September 24, 2018
Phase: Phase 1
Study type: Interventional

The overall aim of this study is to evaluate the safety, immunogenicity and dose sparing effects of H7N9 influenza antigen formulated with 2 different adjuvants .

NCT ID: NCT01928472 Completed - H7N9 Influenza Clinical Trials

Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

Start date: August 2013
Phase: Phase 1
Study type: Interventional

Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.